Literature DB >> 12938202

High prevalence of HPV 16 in South African women with cancer of the cervix and cervical intraepithelial neoplasia.

Patti Kay1, Robbert Soeters, James Nevin, Lynette Denny, Catherine M C Dehaeck, Anna-Lise Williamson.   

Abstract

Despite the high prevalence of cervical cancer and cervical neoplasias in South Africa, few studies have been performed in this region to establish which human papillomavirus (HPV) types are associated with the development of high-grade cervical intraepithelial neoplasia lesions and cervical cancer. To investigate these prevalence rates, punch biopsies were obtained from 56 women with cervical cancer and 141 women with histologically diagnosed cervical intraepithelial neoplasia 2 or 3 lesions. Nested polymerase chain reaction (PCR) using consensus degenerate PCR primers was performed for the detection of HPV DNA and HPV typing was done by restriction fragment length polymorphism. Forty-seven (94%) of the cervical cancer and 114 (88%) of the cervical intraepithelial neoplasia 2/3 biopsies were positive for HPV DNA. The prevalence rates of the HPV types detected in the cervical cancer biopsies were HPV 16 (82%), HPV 18, (10%), HPV 33 (10%), HPV 31 (2%), HPV 58 (2%), HPV 35 (2%), and HPV 59 (2%). The cervical intraepithelial neoplasia lesions contained HPV 16 (56.6%), HPV 33 (14%), HPV 31 (10.9%), HPV X (7%), HPV 52 (3.9), HPV 58 (3.1%), HPV 35 (2.3%), HPV 18 (1.6%), HPV 11 (0.8%). Five of the nine fragments that were not typed by the RFLP, designated HPV-X, were sequenced to give HPV6 (1/5), HPV 26 (2/5), HPV 68 (1/5), and candHPV 87 (1/5). HPV 58 was detected in one cervical cancer biopsy and four biopsies from cervical intraepithelial neoplasia grade 3 lesions and was shown to be a previously described variant [Williamson and Rybicki (1991) J. Med. Virol. 33:165-171]. In addition, a cervical intraepithelial neoplasia grade 2 lesion was shown to harbour HPV type HAN2294 (cand HPV 87). The results of this study indicate that cervical cancer and cervical intraepithelial neoplasia 2/3 are largely associated with HPV 16 infection in this group of South African women and, therefore, an effective HPV 16 based vaccine should prevent the development of cervical cancer in a large proportion of women from this region of South Africa. Copyright 2003 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2003        PMID: 12938202     DOI: 10.1002/jmv.10479

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  21 in total

Review 1.  The burden of human papillomavirus infections and related diseases in sub-saharan Africa.

Authors:  Hugo De Vuyst; Laia Alemany; Charles Lacey; Carla J Chibwesha; Vikrant Sahasrabuddhe; Cecily Banura; Lynette Denny; Groesbeck P Parham
Journal:  Vaccine       Date:  2013-12-29       Impact factor: 3.641

2.  Comparison of cervical and blood T-cell responses to human papillomavirus-16 in women with human papillomavirus-associated cervical intraepithelial neoplasia.

Authors:  Jo-Ann S Passmore; Michelle Milner; Lynnette Denny; Candice Sampson; Dianne J Marais; Bruce Allan; Pam P Gumbi; Inga I Hitzeroth; Edward P Rybicki; Anna-Lise Williamson
Journal:  Immunology       Date:  2006-10-09       Impact factor: 7.397

3.  Characterization of Single-Nucleotide Polymorphisms in the Tumor Necrosis Factor α Promoter Region and in Lymphotoxin α in Squamous Intraepithelial Lesions, Precursors of Cervical Cancer.

Authors:  Miriam Enriqueta Nieves-Ramirez; Oswaldo Partida-Rodriguez; Pedro Eduardo Alegre-Crespo; Maria Del Carmen Tapia-Lugo; Martha Esthela Perez-Rodriguez
Journal:  Transl Oncol       Date:  2011-12-01       Impact factor: 4.243

4.  Cervical human papillomavirus (HPV) infection and HPV type 16 antibodies in South African women.

Authors:  Dianne J Marais; Debbie Constant; Bruce Allan; Henri Carrara; Margaret Hoffman; Samuel Shapiro; Chelsea Morroni; Anna-Lise Williamson
Journal:  J Clin Microbiol       Date:  2007-12-12       Impact factor: 5.948

5.  Cervical human papillomavirus (HPV) infection in South African women: implications for HPV screening and vaccine strategies.

Authors:  Bruce Allan; Dianne J Marais; Margaret Hoffman; Samuel Shapiro; Anna-Lise Williamson
Journal:  J Clin Microbiol       Date:  2007-10-31       Impact factor: 5.948

6.  The Karyopherin proteins, Crm1 and Karyopherin beta1, are overexpressed in cervical cancer and are critical for cancer cell survival and proliferation.

Authors:  Pauline J van der Watt; Christopher P Maske; Denver T Hendricks; M Iqbal Parker; Lynette Denny; Dhirendra Govender; Michael J Birrer; Virna D Leaner
Journal:  Int J Cancer       Date:  2009-04-15       Impact factor: 7.396

7.  Distribution of HPV genotypes in cervical intraepithelial lesions and cervical cancer in Tanzanian women.

Authors:  Adriana C Vidal; Susan K Murphy; Brenda Y Hernandez; Brandi Vasquez; John A Bartlett; Olola Oneko; Pendo Mlay; Joseph Obure; Francine Overcash; Jennifer S Smith; Mike van der Kolk; Cathrine Hoyo
Journal:  Infect Agent Cancer       Date:  2011-11-14       Impact factor: 2.965

8.  Prevalence of human papillomavirus types associated with cervical lesions in Sergipe state, Northeastern Brazil: high frequency of a possibly carcinogenic type.

Authors:  I G S S Serra; E D Araujo; G S Barros; F L S G Santos; R Q Gurgel; M V A Batista
Journal:  Epidemiol Infect       Date:  2018-05-21       Impact factor: 4.434

9.  The relationship between anti-HPV-16 IgG seropositivity and cancer of the cervix, anogenital organs, oral cavity and pharynx, oesophagus and prostate in a black South African population.

Authors:  Freddy Sitas; Margaret Urban; Lara Stein; Valerie Beral; Paul Ruff; Martin Hale; Moosa Patel; Dianne O'Connell; Xue Qin Yu; Anke Verzijden; Dianne Marais; Anna-Lise Williamson
Journal:  Infect Agent Cancer       Date:  2007-03-02       Impact factor: 2.965

10.  The status of cervical cytology in Swaziland, Southern Africa: a descriptive study.

Authors:  Sylvain Okonda; Colleen Wright; Pam Michelow
Journal:  Cytojournal       Date:  2009-08-06       Impact factor: 2.091

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.